Cargando…
New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
The clinical treatment of DNA-repair defective tumours has been revolutionised by the use of poly(ADP) ribose polymerase (PARP) inhibitors. However, the efficacy of these compounds is hampered by resistance, which is attributed to numerous mechanisms including rewiring of the DNA damage response to...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099596/ https://www.ncbi.nlm.nih.gov/pubmed/37065862 http://dx.doi.org/10.20517/cdr.2022.73 |